HealthTell Working on Accurate Diagnosis For Immune Conditions, Including SLE

HealthTell™, an early stage Life Sciences company, recently announced Chaim Putterman, M.D and John Galgiani, M.D as newly appointed clinical advisors. The company has developed a new technology named Immunosignature™ that accurately detects and monitors chronic illnesses, including Lupus. HealthTell is working on the first platform to diagnose and assess the response of the immune system to particular conditions.

The platform offers clinicians an accurate method to detect either the presence or absence of specific conditions at an early stage, improving clinical outcomes and reducing healthcare costs. The technology can be used in many areas and helps clinicians and their patients to have a proactive management of therapeutic options.

Dr. Galgiani is a leading researcher in the area of infectious diseases (in particular Valley Fever) and has worked in raising awareness and improving outcomes for people affected with the disease. Dr. Galgiani is the Director of the Valley Fever Center for Excellence and also a professor at the University of Arizona College of Medicine and has 35 years of proficiency in medical mycology.

Dr. Chaim Putterman is Chief of the Division of Rheumatology and Professor of Medicine, Microbiology and Immunology at the Albert Einstein College of Medicine in New York. He is the lead researcher in many projects supported by the National Institutes of Health (NIH) focused on systemic lupus erythematosus (SLE).

As a new clinical advisor at HealthTell he will bring his knowledge of this complex disease caused by the exacerbation of antibody production leading to inflammation and damage of tissue. According to the Lupus Foundation of America, approximately 1.5 million Americans suffer with SLE, a condition that usually affects women. Early diagnosis of SLE is pivotal for a better management of the condition.

“HealthTell is excited to welcome Dr. Galgiani and Dr. Putterman to our growing team of Clinical Advisors. They will provide valuable insights to expand our focus beyond oncology to infectious and autoimmune diseases,” said Bill Colston, Ph.D., CEO of HealthTell in a recent news release. “Our robust and unique test provides a snapshot of the immune system’s response to disease. We are grateful to have the opportunity to collaborate with clinicians and researchers of this caliber.”